Thus, the main goals of the current study were: (1) to evaluate if immunohistochemial staining with antibodies of CD10, BCL-6 and MUM1 could define distinct, clinically significant subgroups of gastrointestinal DLBCL; (2) to examine if these subgroups had prognostic significance for patients with gastrointestinal DLBCL; (3) to assess the therapeutic outcomes of the different immunophenotype subgroups. The gene discussed is IRF4; the disease is diffuse large B-cell lymphoma.